Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

  • Post author:
  • Post category:uncategorized

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable…

Continue ReadingPerioperative durvalumab may change standard-of-care for patients with resectable lung cancer